加载中
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
前收盘价
US$2.45
−US$0.05 · -2.00%
盘后
US$2.45
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
日内区间
当前US$2.45
52周区间
当前US$2.45
盘中时间采用ET。市场数据可能有所延迟。
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
日内区间
当前US$2.45
52周区间
当前US$2.45
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CHF） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 357.3万 CHF | 2730.9万 CHF | 1480.1万 CHF | 393.5万 CHF | — |
| 销货成本 | — | 6257万 CHF | 5460.6万 CHF | — | — |
| 毛利 | 357.3万 CHF | −3526.1万 CHF | −3980.5万 CHF | 393.5万 CHF | — |
| 研究与开发 | 5643.6万 CHF | 6257万 CHF | 5460.6万 CHF | 6033.6万 CHF | 6228.2万 CHF |
| 销售、一般及管理费用 | 1165.2万 CHF | 1143.4万 CHF | 1057.6万 CHF | 958.2万 CHF | 1087.9万 CHF |
| 营业费用 | 7243.6万 CHF | 1711.7万 CHF | 1381.9万 CHF | 7478.2万 CHF | 7901万 CHF |
| 利息收入 | 186.5万 CHF | 319.6万 CHF | 104.4万 CHF | 6.9万 CHF | 648.5万 CHF |
| 利息支出 | 19.1万 CHF | 13.3万 CHF | 17.6万 CHF | 35.5万 CHF | 58.1万 CHF |
| 折旧和摊销 | 250.3万 CHF | 216.2万 CHF | 221.5万 CHF | 235.9万 CHF | 240.6万 CHF |
| 营业利润 | −6886.3万 CHF | −5237.8万 CHF | −5362.4万 CHF | −7084.7万 CHF | −7901万 CHF |
| 净利润 | −7044.7万 CHF | −5091.6万 CHF | −5423.3万 CHF | −7075.3万 CHF | −7299.6万 CHF |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$8.33
上涨空间 240.00%报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB118.98万0.01%108.2亿 USD0.44%US$204.26-1.08%
Dimensional - US Small Cap ETFDFAS31.53万0.00%338.04亿 USD0.31%US$78.17-0.23%
U.S. Micro Cap Portfolio ETFDFMC11.02万0.00%75.44亿 USD0.43%US$57.70-0.20%
U.S. Vector Equity Portfolio ETF Class SharesDXUV3.96万0.00%61.96亿 USD0.26%US$68.32+0.06%
Dimensional - US Core Equity 2 ETFDFAC1.97万0.00%885.59亿 USD0.21%US$45.31-0.04%
Invesco Nasdaq Biotechnology ETFIBBQ1.89万0.02%1.12亿 USD0.19%US$34.2482-1.07%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.44万0.00%455.76亿 USD0.17%US$84.43-0.01%
ProShares Ultra Nasdaq BiotechnologyBIB9579.50.01%9138.97万 USD1.19%US$108.79-1.90%iShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACInvesco Nasdaq Biotechnology ETFIBBQU.S. Core Equity 1 Portfolio ETF Class SharesDCORProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
